Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Gloster Biomedical
Durham, North Carolina, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Gloster Biomedical is a preclinical-stage biotechnology company focused on developing small molecule therapies for neurodegenerative and lysosomal storage disorders. The company's lead research programs center on the development of pharmacological chaperones designed to restore the activity of the GBA1 enzyme. This approach targets the underlying genetic drivers of GBA-associated Parkinson's disease and Gaucher disease. Gloster Biomedical leverages deep expertise in protein trafficking and lysosomal function to advance its pipeline of disease-modifying treatments.
- Therapeutic areas
- NeurologyRare Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Michael J. Fox Foundation
Beyond the preview
Go deeper on Gloster Biomedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gloster Biomedical.